[27/08/2009] Georges De Vos named COO, Results 1H09
Georges De Vos named COO of Omega Pharma
Georges De Vos (photo) is appointed Chief Operating Officer (COO) of Omega Pharma. In this function, he joins the Executive Committee and reports directly to CEO Marc Coucke.
After careers at Procter & Gamble, Duracell and ALJ-Toyota, he was recruited in 1997 by Novartis Consumer Health, where he developed an international career, characterized by the continuous combination of sales growth, innovation and operational excellence.
Since 1 September 2009, the Executive Committee of Omega Pharma consists of 7 members: Marc Coucke (Chief Executive Officer), Georges De Vos (Chief Operating Officer), Mario Debel (Head of Marketing & Innovation), Barbara De Saedeleer (Chief Strategy Officer), Ton Scheepens (Head of Operations (West)) and Jan Cassiman (Head of Operations (East) & Business Development).
Read the full press release.
Results First Half 2009
1.67 euro recurring earnings per share after only six months thanks to structural cost savings in a most difficult sales period
The turnover of Omega Pharma, the specialist in non-prescription medicines and health products, decreased by 3% in the first half of 2009 to 411 million euro. The gross margin was 54.4%. Thanks to over 20 million euro of cost savings, Omega Pharma managed to post an EBITDA of 67.4 million euro in spite of the current difficult macro-economic conditions. As a result, the net recurring EPS for the first half of 2009 has already reached 1.67 euro. These positive results and lower financial charges, combined with a limited capex and an improved working capital has led to major free cash flow generation. More.
Comments to the turnover (trading update dd. 16 July 2009)
